文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

体外二氧化碳清除对气体交换与呼吸机设置的影响:系统评价与荟萃分析

Effects of extracorporeal CO2 removal on gas exchange and ventilator settings: a systematic review and meta-analysis.
PubMed 文献 · Crit Care · 2024-04-30
一句话结论ECCO2R可显著降低PaCO2、平台压与潮气量并升高pH,但3项RCT未显示生存获益且ICU与住院时间延长、不良事件增加。

该系统评价与荟萃分析纳入2000年1月至2022年3月间49项研究共1672例接受ECCO2R的成人ICU呼吸衰竭患者,主要终点为ECCO2R启动后24小时气体交换与呼吸机设置变化。结果显示ECCO2R与PaCO2、平台压和潮气量显著下降及pH升高相关,总体不良事件率19%;ARDS与肺移植患者PaO2/FiO2显著升高而呼吸机设置变化不定。3项RCT未显示死亡率获益,但ECCO2R组ICU与住院时间显著延长,临床结局影响仍不明确。

要点

  • 49项研究1672例成人ICU呼吸衰竭患者,ECCO2R启动24小时后PaCO2、平台压、潮气量显著下降,pH升高。
  • 总体不良事件率19%。
  • 3项RCT未显示死亡率获益,ECCO2R组ICU与住院时间显著延长。
  • ARDS与肺移植患者PaO2/FiO2显著升高,但呼吸机设置变化不定。
  • 「高提取」系统降低PaCO2与呼吸频率更有效。

适用人群与场景

  • 成人ICU呼吸衰竭患者,接受ECCO2R治疗。
  • 亚组包括ARDS与肺移植患者。

研究设计与关键结果

  • 系统评价与荟萃分析,纳入2000年1月至2022年3月的观察性研究与RCT,共49项研究、1672例患者。
  • ECCO2R启动后24小时,所有患者组PaCO2、平台压、潮气量显著下降,pH升高;总体不良事件率19%。
  • ARDS与肺移植患者PaO2/FiO2显著升高,呼吸机设置变化不定。
  • 「高提取」系统较其他系统更有效地降低PaCO2与呼吸频率。
  • 3项RCT未显示ECCO2R对死亡率有影响,但ECCO2R与ICU和住院时间显著延长相关。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入观察性研究与随机对照试验。
  • PROSPERO注册号CRD 42020154110(2021年1月24日)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • ECCO2R可有效降低PaCO2与酸中毒,从而允许创伤更小的通气;「高提取」系统可能更有效地实现该目标(作者认为)。
  • RCT未显示死亡率获益且不良事件增加,ECCO2R对临床结局的影响仍不明确;未来研究应针对可能获益的患者群体(作者认为)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: A systematic review and meta-analysis to evaluate the impact of extracorporeal carbon dioxide removal (ECCO2R) on gas exchange and respiratory settings in critically ill adults with respiratory failure.

METHODS: We conducted a comprehensive database search, including observational studies and randomized controlled trials (RCTs) from January 2000 to March 2022, targeting adult ICU patients undergoing ECCO2R. Primary outcomes were changes in gas exchange and ventilator settings 24 h after ECCO2R initiation, estimated as mean of differences, or proportions for adverse events (AEs); with subgroup analyses for disease indication and technology. Across RCTs, we assessed mortality, length of stay, ventilation days, and AEs as mean differences or odds ratios.

RESULTS: A total of 49 studies encompassing 1672 patients were included. ECCO2R was associated with a significant decrease in PaCO2, plateau pressure, and tidal volume and an increase in pH across all patient groups, at an overall 19% adverse event rate. In ARDS and lung transplant patients, the PaO2/FiO2 ratio increased significantly while ventilator settings were variable. "Higher extraction" systems reduced PaCO2 and respiratory rate more efficiently. The three available RCTs did not demonstrate an effect on mortality, but a significantly longer ICU and hospital stay associated with ECCO2R.

CONCLUSIONS: ECCO2R effectively reduces PaCO2 and acidosis allowing for less invasive ventilation. "Higher extraction" systems may be more efficient to achieve this goal. However, as RCTs have not shown a mortality benefit but increase AEs, ECCO2R's effects on clinical outcome remain unclear. Future studies should target patient groups that may benefit from ECCO2R. PROSPERO Registration No: CRD 42020154110 (on January 24, 2021).

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Stommel AM, Herkner H, Kienbacher CL, et al. Effects of extracorporeal CO2 removal on gas exchange and ventilator settings: a systematic review and meta-analysis. Crit Care. 2024. PMID: 38693569. doi:10.1186/s13054-024-04927-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。